Ajanta Pharma

{
  "main_header": {
    "sid": 178818,
    "name": "Ajanta Pharma",
    "stock_name": "Ajanta Pharma",
    "full_name": "Ajanta Pharma Ltd.",
    "name_url": "stocks-analysis/ajanta-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "3,512.50",
    "chg": 48.05,
    "chgp": "1.39%",
    "dir": 1,
    "prev_price": "3,464.45",
    "mcapval": "43,544.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532331,
    "symbol": "AJANTPHARM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE031B01049",
    "curr_date": "Sep 07, 03:30 PM",
    "curr_time": "08:03 AM",
    "last_traded_at": "Sep 07, 03:30 PM IST",
    "bse_nse_vol": "73.91 k",
    "exc_status": "Active",
    "traded_date": "Sep 07, 2026",
    "traded_date_str": "2026 09 07",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ajanta-pharma-178818-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Ajanta Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-downgraded-to-hold-amid-mixed-technical-and-valuation-signals-4184908",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4184908.png",
        "date": "2026-09-07 08:07:16",
        "description": "Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 September 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong recent financial results and long-term outperformance, evolving market dynamics and valuation pressures have tempered investor enthusiasm."
      },
      {
        "title": "Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-technical-momentum-shifts-amid-mixed-market-signals-4184397",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_technicaldot_4184397.png",
        "date": "2026-09-07 08:00:26",
        "description": "Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock continues to demonstrate resilience with strong long-term returns, though short-term indicators suggest caution for investors."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-hold-by-marketsmojo-4183189",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/AjantaPharmaLtd_mojoScore_4183189.png",
        "date": "2026-09-05 10:10:16",
        "description": "Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with the most up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/ajanta-pharma-ltd-is-rated-buy-by-marketsmojo-4168526",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_mojoScore_4168526.png",
        "date": "2026-08-25 10:11:15",
        "description": "Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook."
      },
      {
        "title": "Ajanta Pharma Ltd: Valuation Shift Signals Price Attractiveness Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-valuation-shift-signals-price-attractiveness-amid-strong-returns-4166336",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_valuationdot_4166336.png",
        "date": "2026-08-24 08:00:07",
        "description": "Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid robust financial performance and relative comparisons with peers, prompting investors to reassess the stock’s price attractiveness in the current mid-cap landscape."
      },
      {
        "title": "Ajanta Pharma’s 0.95% Weekly Dip Masks Strong 52-Week Highs and Premium Valuation",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharmas-095-weekly-dip-masks-strong-52-week-highs-and-premium-valuation-4166185",
        "imagepath": "",
        "date": "2026-08-23 15:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>17 Aug:</strong> New 52-week high at Rs.3,722.15 and all-time high at Rs.3,705</p>\n                    <p><strong>18 Aug:</strong> Further 52-week and all-time high at Rs.3,790.85</p>\n                    <p><strong>19 Aug:</strong> Minor gain amid broader market weakness</p>\n                    <p><strong>20 Aug:</strong> Notable decline of 1.04% despite Sensex rebound</p>\n                    <p><strong>21 Aug:</strong> Continued pullback, closing at Rs.3,640.35 (-0.69%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.3,675.15</div></div>\n               ..."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3790.85",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-hits-new-52-week-high-at-rs379085-4159340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_priceRelatedfactors_4159340.png",
        "date": "2026-08-18 09:48:36",
        "description": ""
      },
      {
        "title": "Ajanta Pharma Ltd. Hits All-Time High of Rs 3,790.85 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharma-ltd-stock-hits-all-time-high-at-rs-379085-4159230",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_priceRelatedfactors_4159230.png",
        "date": "2026-08-18 09:31:56",
        "description": ""
      },
      {
        "title": "Ajanta Pharma’s Valuation Shifts to Very Expensive Amid Strong Market Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ajanta-pharmas-valuation-shifts-to-very-expensive-amid-strong-market-outperformance-4158428",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/AjantaPharmaLtd_valuationdot_4158428.png",
        "date": "2026-08-18 08:00:15",
        "description": "Ajanta Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, reflecting evolving market perceptions and price attractiveness. This article analyses the recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 692,
    "sid": "178818",
    "stock_news_url": "https://www.marketsmojo.com/news/ajanta-pharma-178818"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "31-Aug-2026",
      "details": "Pls find enclosed newspaper publication for transfer of equity shares to IEPF.",
      "source": "BSE"
    },
    {
      "caption": "Participation In Investor Conference",
      "datetime": "31-Aug-2026",
      "details": "Pls find enclosed Intimation w.r.t Participation in Investor Conference.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "27-Aug-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 27 2026 for Aayush Agrawal trustee Aayush Agrawal Trust",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has declared <strong>1600%</strong> dividend, ex-date: 05 Aug 26",
          "dt": "2026-08-05",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>2:5</strong> stock split, ex-date: 20 Mar 15",
          "dt": "2015-03-20",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Ajanta Pharma Ltd. has announced <strong>1:2</strong> bonus issue, ex-date: 22 Jun 22",
          "dt": "2022-06-22",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Ajanta Pharma Downgraded to Hold Amid Mixed Technical and Valuation Signals

2026-09-07 08:07:16

Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 4 September 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technical indicators. Despite strong recent financial results and long-term outperformance, evolving market dynamics and valuation pressures have tempered investor enthusiasm.

Read full news article

Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals

2026-09-07 08:00:26

Ajanta Pharma Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock continues to demonstrate resilience with strong long-term returns, though short-term indicators suggest caution for investors.

Read full news article

Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO

2026-09-05 10:10:16

Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 September 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 05 September 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

Ajanta Pharma Ltd. is Rated Buy by MarketsMOJO

2026-08-25 10:11:15

Ajanta Pharma Ltd. is rated 'Buy' by MarketsMOJO, with this rating last updated on 30 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 August 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Read full news article

Ajanta Pharma Ltd: Valuation Shift Signals Price Attractiveness Amid Strong Returns

2026-08-24 08:00:07

Ajanta Pharma Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating. This change reflects evolving market perceptions amid robust financial performance and relative comparisons with peers, prompting investors to reassess the stock’s price attractiveness in the current mid-cap landscape.

Read full news article

Ajanta Pharma’s 0.95% Weekly Dip Masks Strong 52-Week Highs and Premium Valuation

2026-08-23 15:00:05

Key Events This Week

17 Aug: New 52-week high at Rs.3,722.15 and all-time high at Rs.3,705

18 Aug: Further 52-week and all-time high at Rs.3,790.85

19 Aug: Minor gain amid broader market weakness

20 Aug: Notable decline of 1.04% despite Sensex rebound

21 Aug: Continued pullback, closing at Rs.3,640.35 (-0.69%)

Week Open

Rs.3,675.15

...

Read full news article

Broad-Based Technical Strength Lifts Ajanta Pharma Ltd. to 52-Week High of Rs 3790.85

2026-08-18 09:48:36

Read full news article

Ajanta Pharma Ltd. Hits All-Time High of Rs 3,790.85 as Momentum Builds Across Timeframes

2026-08-18 09:31:56

Read full news article

Ajanta Pharma’s Valuation Shifts to Very Expensive Amid Strong Market Outperformance

2026-08-18 08:00:15

Ajanta Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, reflecting evolving market perceptions and price attractiveness. This article analyses the recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News